ARCHIVES

How Low Can You Go? ODAC Accepts Retrospective Study for Accelerated Approval

This article is from The Cancer Letter archive.

Vol. 37 No. 36 | September 30, 2011

Download PDF Visit The Full Archive

Related Articles

Professional Societes; ASCO’s Strength Is In Its Diversify, Lichtor Says

May 21, 1999

ODAC Votes 13:0 to Recommend Perjeta for Accelerated Approval

September 13, 2013

Monoclonal Antibody Improves AML Response To Therapy

July 26, 2002

In Brief: No End Of The Year Hassle His Time – NCI Full Appropriation for FY 1977 Released

November 19, 1976

NCI Picks 11 Centers For Chemical Biology Consortium

October 23, 2009

Black Men Face Disparate Cancer Burden; Minority Rates Vary, Klausner Tells House

April 3, 1998